TP53 and ovarian cancer: Only 3% of the prioritized variants are described in the breast (TP53 and MLH1 variants) and ovarian cancer (BRCA2 variant) samples of The Cancer Genome Atlas database (TCGA) (https://www.cbioportal.org/), which is expected once the publicly available data on TCGA comprises solely somatic variants.